The selective HDAC1 inhibitor entinostat (MS-275) improved behavioral activities in the AD-APPPS1-21 mouse model by reducing amyloid plaque deposition and neuroinflammatory processes [187], while the mercaptoacetamide-based class II HDACi (W2) improved memory tasks and reduced tau phosphorylation rates and Aβ deposition in triple transgenic 3xTg-AD mice [188]. Here, MAPT is linked to Alzheimer disease.